Proscia expands into international digital pathology market to help with rising cancer burden

Feb. 20, 2020

Proscia, a leading provider of artificial intelligence (AI) enabled digital pathology solutions, has expanded into the international diagnostic pathology market to meet the growing needs of laboratories and cancer patients worldwide. The company has added the leadership of Arun Ananthapadmanabhan as Executive Vice President, Global Growth, to manage commercial operations for its international market. Proscia’s accelerated global focus follows the company’s November announcement that it received CE Mark for its Concentriq Dx solution for use in primary diagnosis.

Digital pathology has experienced broad adoption in international markets, where the regulatory landscape and a severely declining pathologist population have encouraged laboratories to implement image-based workflows. These laboratories are realizing the benefits of digitization, including improved efficiency and productivity. A notable example of successful digitization is Spain’s Granada University Hospitals, where pathologists have signed out, on average, 21percent more cases each year since implementing a full digital pathology program for primary diagnosis. Digital laboratories are now poised to adopt AI-based computational applications, which will further enhance efficiency and expand the breadth of critical diagnostic information available to improve patient outcomes.

“The European digital pathology market is demonstrating tremendous potential in the face of critical challenges,” said Steve Holloway, Company Director & Principal Analyst at Signify Research. “In a recent workforce census conducted by the Royal College of Pathologists, only three percent of UK pathology departments reported having enough staff to meet clinical demand. Shortages like these are being blamed for ultimately delaying cancer treatment, and the continued adoption of digital pathology and use of artificial intelligence will play a major part in addressing these issues.”

Proscia’s Concentriq digital pathology platform operates at the center of the modern, image-based laboratory. Its end-to-end capabilities include automation of time-consuming and error-prone manual tasks, streamlined collaboration and delivery of deeper operational insights into the hands of laboratory managers. Concentriq is an open, flexible platform that works with any scanner and laboratory information system (LIS), offering seamless integrations with Philips, Leica, 3DHISTECH, Roche and Hamamatsu among other leading whole slide image scanners. It also serves as a launchpad for the company’s suite of AI applications, enabling laboratories to easily deploy AI in practice.

Visit Proscia for more news